A detailed history of Voya Investment Management LLC transactions in Immunovant, Inc. stock. As of the latest transaction made, Voya Investment Management LLC holds 65,046 shares of IMVT stock, worth $1.79 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares
65,046
Previous 80,910 19.61%
Holding current value
$1.79 Million
Previous $2.61 Million 34.32%
% of portfolio
0.0%
Previous 0.0%

Shares

12 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Aug 14, 2024

SELL
$25.1 - $31.61 $398,186 - $501,461
-15,864 Reduced 19.61%
65,046 $1.72 Million
Q1 2024

May 15, 2024

SELL
$30.27 - $43.79 $116,448 - $168,460
-3,847 Reduced 4.54%
80,910 $2.61 Million
Q4 2023

Feb 14, 2024

SELL
$31.31 - $44.19 $713,742 - $1.01 Million
-22,796 Reduced 21.2%
84,757 $3.57 Million
Q3 2023

Nov 14, 2023

BUY
$18.55 - $39.96 $1.6 Million - $3.44 Million
86,174 Added 403.08%
107,553 $4.13 Million
Q2 2023

Aug 14, 2023

BUY
$14.2 - $23.75 $64,808 - $108,395
4,564 Added 27.14%
21,379 $405,000
Q4 2022

Feb 14, 2023

BUY
$6.59 - $17.75 $9,212 - $24,814
1,398 Added 9.07%
16,815 $298,000
Q3 2022

Mar 03, 2023

SELL
$3.93 - $6.37 $5,494 - $8,905
-1,398 Reduced 8.31%
15,417 $86,000
Q4 2021

Feb 14, 2022

BUY
$7.33 - $9.32 $989 - $1,258
135 Added 0.88%
15,417 $131,000
Q2 2021

Aug 16, 2021

SELL
$9.4 - $16.85 $18,170 - $32,571
-1,933 Reduced 11.23%
15,282 $162,000
Q1 2021

May 17, 2021

BUY
$13.08 - $49.6 $18,011 - $68,299
1,377 Added 8.69%
17,215 $276,000
Q4 2020

Feb 16, 2021

BUY
$36.36 - $52.71 $150,530 - $218,219
4,140 Added 35.39%
15,838 $732,000
Q3 2020

Nov 16, 2020

BUY
$22.61 - $38.9 $264,491 - $455,052
11,698 New
11,698 $412,000

Others Institutions Holding IMVT

About Immunovant, Inc.


  • Ticker IMVT
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 129,077,000
  • Market Cap $3.55B
  • Description
  • Immunovant, Inc., a clinical-stage biopharmaceutical company, develops monoclonal antibodies for the treatment of autoimmune diseases. It develops batoclimab, a novel fully human monoclonal antibody that selectively binds to and inhibits the neonatal fragment crystallizable receptor, which is in Phase IIa clinical trials for the treatment of mya...
More about IMVT
Track This Portfolio

Track Voya Investment Management LLC Portfolio

Follow Voya Investment Management LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Voya Investment Management LLC, based on Form 13F filings with the SEC.

News

Stay updated on Voya Investment Management LLC with notifications on news.